T Cell Receptor Based Therapy of Metastatic Colorectal Cancer

Phase 1/2 Terminated 1 enrolled Oslo University Hospital

NaSingle-groupOpen-labelTreatment

Summary

T Cell Receptor Based Therapy of Metastatic Colorectal Cancer With mRNA-engineered T Cells Targeting Transforming Growth Factor Beta Receptor Type II (TGFβII)

Timeline

Start: 2018-03-08
Primary completion: 2019-06-12
Completion: 2019-06-12

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Publications

Maggadottir SM, Dueland S, Mensali N, Hamre H, Andresen PA, Myhre MR, Juul HV, Bigalke I, Lundby M, Honnashagen TK, Saeboe-Larssen S, Josefsen D, Hagtvedt T, Walchli S, Kvalheim G, Inderberg EM. Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer. Mol Ther. 2024 Jun 5;32(6):2021-2029. doi: 10.1016/j.ymthe.2024.04.009. Epub 2024 Apr 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Radium-1 TCR	Cell therapy	2e+09 cells	Intravenous